The next steps will be to develop these new and improved macrolide antibiotics — , which Dr. Berghuis estimates will take another two to three years — and to then test them.
We identified variants that displayed improved sensitivity towards erythromycin, tailored the inducer specificity, and significantly improved sensitivity to macrolides that were very poor inducers of the wild - type MphR biosensor.